Anavex Life Sciences (AVXL) Liabilities and Shareholders Equity (2011 - 2025)

Anavex Life Sciences' Liabilities and Shareholders Equity history runs 15 years deep, the most recent figure standing at $133.0 million for Q4 2025.

• In Q4 2025, Liabilities and Shareholders Equity rose 7.21% year-over-year to $133.0 million; the TTM figure through Dec 2025 stood at $456.4 million (down 16.36% YoY), while the FY2025 annual figure was $103.8 million, down 23.42% from the prior year.
• Liabilities and Shareholders Equity came in at $133.0 million for Q4 2025 at Anavex Life Sciences, up from $103.8 million in the prior quarter.
• In the past five years, Liabilities and Shareholders Equity ranged from a high of $166.4 million in Q2 2021 to a low of $83.6 million in Q1 2021.
• A 5-year average of $140.6 million and a median of $148.2 million in 2022 frame the typical range for Liabilities and Shareholders Equity.
• Across the five-year window, Liabilities and Shareholders Equity jumped 426.14% in 2021 and dropped 27.63% in 2025, its largest moves.
• Anavex Life Sciences' Liabilities and Shareholders Equity stood at $156.9 million in 2021, then dropped by 5.43% to $148.4 million in 2022, then fell by 0.2% to $148.1 million in 2023, then dropped by 16.23% to $124.0 million in 2024, then climbed by 7.21% to $133.0 million in 2025.
• According to Business Quant data, Liabilities and Shareholders Equity over the past three periods registered $133.0 million, $103.8 million, and $102.4 million for Q4 2025, Q3 2025, and Q2 2025 respectively.

Peer Comparison